Immunoglobulin G4 (IgG4) Related Disease
Are you Eligible?Testing new treatments for people with IgG4 related disease (fibro-inflammatory condition).
Research Objectives
Status
Estimated completion
Total participants required
Study location
About this clinical trial
There are currently no medicinal products approved for the treatment of IgG4-RD. The majority of cases follow a relapsing course that can lead to permanent tissue damage with potential morbidity and mortality. This project aims to develop an effective product.
The purpose of this study is to better understand the safety and side effects of Inebilizumab and to find out if it helps people with IgG4 related disease.
Eligibility
Do you meet the following criteria?
Adults aged ≥ 18 years who have recently active IgG4-RD (initial diagnosis or flare) that requires new or ongoing treatment, are at high risk of future flare, and meet the 2019 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR)IgG4-RD classification criteria.
Additional information
You can find out more about the MITIGATE trial by visiting the ClinicalTrials.gov website.
Lead investigators
- Dr Daman Langguth
Technical title
A Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in Immunoglobulin G4-related disease (IgG4) Related Disease (MITIGATE)
Register your interest
If you would like more information about this clinical trial, please complete the contact form below.